Mesothelioma - Hitt Medical Writing, LLC

Mesothelioma HittPackTM


Contents I.

Disease and Treatment Information in Mesothelioma ......................................................................... 2

II.

Recent News Articles in Mesothelioma ................................................................................................. 2 Medscape Medical News (free password required).................................................................................. 2 MedpageToday ......................................................................................................................................... 2 Reuters Health........................................................................................................................................... 3

III. Press Releases in Mesothelioma ........................................................................................................... 3 Eurekalert.org ........................................................................................................................................... 3 Newswise.com .......................................................................................................................................... 8 Google.com ............................................................................................................................................... 9 IV. US Food and Drug Administration Info on Mesothelioma .................................................................. 11 Drugs@FDA Database ............................................................................................................................ 11 2011 Advisory Committee Meetings ....................................................................................................... 13 V.

Guidelines in Mesothelioma ................................................................................................................ 13 National Guidelines Clearinghouse--Guidelines.gov ............................................................................... 14 National Comprehensive Cancer Network .............................................................................................. 14 European Society for Medical Oncology (ESMO) .................................................................................... 15

VI. Conferences and Medical Associations for Mesothelioma ................................................................. 15 Conferences ............................................................................................................................................. 15 Medical Associations............................................................................................................................... 15 VII. Key Opinion Leaders in Mesothelioma ................................................................................................ 15 VIII. Clinical Trials in Progress in Mesothelioma......................................................................................... 16 IX. PubMed Search in Mesothelioma ....................................................................................................... 20 Randomized Controlled Trials ................................................................................................................. 20 Reviews ................................................................................................................................................... 21 Editorials ................................................................................................................................................. 25

Hitt Medical Writing, LLC © 2011

www.hittmedicalwriting.com

Page 1


I.

Disease and Treatment Information in Mesothelioma



American Lung Association - General Information on Mesothelioma http://www.lungusa.org/lung-disease/mesothelioma/



American Cancer Society – Information on Malignant Mesothelioma http://www.cancer.org/Cancer/MalignantMesothelioma/DetailedGuide/index



American Society of Clinical Oncology- Mesothelioma Oncologist-approved cancer information from the American Society of Clinical Oncology http://www.cancer.net/patient/Cancer+Types/Mesothelioma



MedlinePlus at the NIH – Mesothelioma Information http://www.nlm.nih.gov/medlineplus/mesothelioma.html



emedicine.medscape.com - Mesothelioma http://emedicine.medscape.com/article/280367-overview

II.

Recent News Articles in Mesothelioma

Medscape Medical News (free password required) http://www.medscape.com/; search term = mesothelioma; all results for the past 3 months.  Largest Trial So Far in Mesothelioma DisappointsNo improvement in overall survival or any other measure was seen in the largest trial conducted so far in patients with malignant pleural mesothelioma. News, Medscape Medical News, September 2011  Helical Tomotherapy Enhances Local Control of Mesothelioma... tomotherapy can achieve excellent local control of malignant pleural mesothelioma (MPM), researchers from France and Canada reported online June 12th in ... News, Reuters Health Information, July 2011  Gene Transfer Promising in Malignant Pleural Mesothelioma Preliminary work suggests intrapleural adenoviral-mediated interferon-alpha 2b gene transfer may be useful against pleural mesothelioma, researchers report. News, Reuters Health Information, July 2011

MedpageToday http://www.medpagetoday.com/; search term = mesothelioma; all results for the past 3 months. ECCO-ESMO: Drug for Mesothelioma Fails Trial 9/28/2011 STOCKHOLM -- Vorinostat (Zolinza) failed to Hitt Medical Writing, LLC © 2011


Page 2

Mesothelioma HittPackTM extend survival as a second-line therapy in patients with malignant pleural mesothelioma, researchers said here.

Reuters Health http://www.reuters.com; search term = mesothelioma; all results for the past 3 months. PRESS DIGEST-Australian General News - Aug 31 ... Page 1. --A Supreme Court jury in Victoria yesterday awarded A$1.15 million in compensation to a 62-year-old mesothelioma sufferer, finding that he had been ... Tue Aug 30, 2011 5:07pm EDT MetLife says asbestos claims on the rise ... Late-night cable television is flooded with ads from asbestos lawyers, and "mesothelioma" is among the most valuable of advertising keywords on Google. ... Fri Aug 5, 2011 8:37am EDT Analysis: New asbestos charges point to reserve woes ... While medical evidence suggests fewer new cases of asbestosis and the lung cancer mesothelioma, insurers say they are getting sued more frequently and ... Thu Jul 28, 2011 11:07am EDT UPDATE 3-Hartford warns after disasters, asbestos losses ... losses. The company said it saw more and larger claims for mesothelioma, an asbestos-linked cancer, than it had expected. Earlier ... Wed Jul 13, 2011 5:16pm EDT

III. Press Releases in Mesothelioma Eurekalert.org www.eurekalert.org; search term = mesothelioma; all results for 2011; sorted by relevance. Hitt Medical Writing, LLC © 2011


Page 3

Mesothelioma HittPackTM NIH-funded researchers discover genetic link to mesothelioma ... researchers discover genetic link to mesothelioma ... developing two forms of cancer – mesothelioma, and melanoma of the eye ... fibers, their risk of developing mesothelioma, an aggressive cancer of the ... http://www.eurekalert.org/pub_releases/2011-08/ncinrd082511.php- 12.8KB - Public Press Releases

78%

UH Cancer Center receives $3.58 million gift for mesothelioma research ... anonymous donor to support the mesothelioma research of Dr. Michele Carbone ... 3.58 million gift for mesothelioma research ... anonymous donor to support the mesothelioma research of Dr. Michele Carbone ... http://www.eurekalert.org/pub_releases/2011-06/uohcucc062311.php- 8.2KB - Public Press Releases

77%

Renal cancer drug temsirolimus shows promise against mesothelioma ... drug temsirolimus shows promise against mesothelioma ... the growth of malignant pleural mesothelioma cells. Mesothelioma, a cancer that is usually ... growth-stopping, effect on all mesothelioma cells. However, mesothelioma cells that were resistant to ... http://www.eurekalert.org/pub_releases/2011-05/iaftrcd042611.php- 9.0KB - Public Press Releases

77%

New study finds cancer-causing mineral in US road gravel ... roads may increase risk of mesothelioma ... an increased risk of developing mesothelioma, a type of cancer of ... lung grow abnormally, leading to mesothelioma, a form of lung cancer ... http://www.eurekalert.org/pub_releases/2011-07/uohcnsf072511.php- 10.5KB - Public Press Releases

75%



||||||||||||||||||||

28 Aug 11 Find Similar Highlight

||||||||||||||||||||

23 Jun 11 Find Similar Highlight

||||||||||||||||||||

01 May 11 Find Similar Highlight

||||||||||||||||||||

25 Jul 11 Find Similar Highlight

Page 4

Mesothelioma HittPackTM Combination therapy shows promise for rare, deadly cancer caused by asbestos ... results for overall survival in mesothelioma patients ... Philadelphia – Pleural mesothelioma patients who undergo lungsparing ... traditional lung sacrificing surgery for mesothelioma, the patients in our study ... http://www.eurekalert.org/pub_releases/2011-06/uopscts060211.php- 13.3KB - Public Press Releases

65%

Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder ... and related cancers, such as mesothelioma. ... of the deadly lung cancer mesothelioma, and in some instances of ... AAAS and EurekAlert! are not responsible for the ... http://www.eurekalert.org/pub_releases/2011-04/twiwrf041511.php- 10.0KB - Public Press Releases

61%

New test detects early-stage, asbestos-related pulmonary cancer ... or stage 2 malignant pleural mesothelioma. The study shows the test ... Malignant pleural mesothelioma is an aggressive, asbestos-related ... to benefit from therapy in mesothelioma are those that are found ... http://www.eurekalert.org/pub_releases/2011-04/nlmcntd032811.php- 8.3KB - Public Press Releases

58%

Protein test detects early-stage, asbestos-related pulmonary cancer ... 19 cases of malignant pleural mesothelioma that were in stage 1 ... 90 patients diagnosed with malignant mesothelioma and 80 participants who had ... derive 19 significant biomarkers for mesothelioma and the remaining 25 percent ... http://www.eurekalert.org/pub_releases/2011-04/aafcptd032511.php- 10.1KB - Public Press Releases

58%



||||||||||||||||||||


||||||||||||||||||||

15 Apr 11 Find Similar Highlight

||||||||||||||||||||


||||||||||||||||||||


Page 5

Mesothelioma HittPackTM Catching cancer early: AACR highlights innovative diagnostic methods ... 19 cases of malignant pleural mesothelioma that were in stage 1 ... 90 patients diagnosed with malignant mesothelioma and 80 participants who had ... derive 19 significant biomarkers for mesothelioma and the remaining 25 percent ... http://www.eurekalert.org/pub_releases/2011-04/aafccce032511.php- 15.7KB - Public Press Releases

49%

Nanotubes could pose health risk to production line staff, study suggests ... a type of cancer known as mesothelioma. Researchers ... they can cause diseases including mesothelioma. ... AAAS and EurekAlert! are not responsible for the ... http://www.eurekalert.org/pub_releases/2011-06/uoencp061411.php- 6.9KB - Public Press Releases

46%

Nanotubes could pose health risk to production line staff, study suggests ... a type of cancer known as mesothelioma. Researchers ... they can cause diseases including mesothelioma. ... AAAS and EurekAlert! are not responsible for the ... http://www.eurekalert.org/pub_releases/2011-06/uoencp061411.php- 6.9KB - Public Press Releases

46%

NYU Cancer Institute experts present at the AACR 102nd Annual Meeting 2011 ... Detection of Mesothelioma in Asbestos Exposed Individuals with ... Malignant pleural mesothelioma is an aggressive, asbestos-related ... or stage 2 malignant pleural mesothelioma. The goal of the new ... http://www.eurekalert.org/pub_releases/2011-04/nlmcnci040111.php- 18.8KB - Public Press Releases

45%



||||||||||||||||||||


||||||||||||||||||||


||||||||||||||||||||


||||||||||||||||||||


Page 6

Mesothelioma HittPackTM IPF lung disease numbers are rising quickly to become a significant cause of mortality in ... ... from ovarian cancer, lymphoma, leukaemia, mesothelioma or kidney cancer. ... AAAS and EurekAlert! are not responsible for the ... of news releases posted to EurekAlert! by contributing institutions or for ... http://www.eurekalert.org/pub_releases/2011-04/bmjild042611.php- 7.5KB - Public Press Releases

39%

Immune system may guide chemotherapy for breast cancer ... PLX3397 in other cancers, including mesothelioma, where blocking macrophage recruitment also ... AAAS and EurekAlert! are not responsible for the ... of news releases posted to EurekAlert! by contributing institutions or for ... http://www.eurekalert.org/pub_releases/2011-04/aafcism032511.php- 9.0KB - Public Press Releases

39%

Deaths and major morbidity from asbestos-related diseases in Asia likely to surge in next ... ... Asbestos related lung diseases, particularly mesothelioma, lung cancer and asbestosis (asbestos ... AAAS and EurekAlert! are not responsible for the ... of news releases posted to EurekAlert! by contributing institutions or for ... http://www.eurekalert.org/pub_releases/2011-06/wdam060911.php- 7.1KB - Public Press Releases

38%

Press program announced for 2011 World Conference on Lung Cancer ... trials related to lung cancer, mesothelioma and thymoma ... AAAS and EurekAlert! are not responsible for the ... of news releases posted to EurekAlert! by contributing institutions or for ... http://www.eurekalert.org/pub_releases/2011-05/iaftppa051611.php- 10.8KB - Public Press Releases

35%



||||||||||||||||||||


||||||||||||||||||||


||||||||||||||||||||


||||||||||||||||||||


Page 7

Mesothelioma HittPackTM Genetically modified 'serial killer' T cells obliterate tumors in leukemia patients ... engineered a CAR vector that binds to mesothelin, a protein expressed on the surface of mesothelioma cancer cells, as well as on ovarian and pancreatic cancer cells. In addition to ... http://www.eurekalert.org/pub_releases/2011-08/uopsgm080411.php- 14.2KB - Public Press Releases

31%

||||||||||||||||||||

10 Aug 11 Find Similar Highlight

Newswise.com www.newswise.com; search term = mesothelioma, all results for 2011; sorted by relevance sorted by date. Results 1 through 10 of 78 Combination Therapy Shows Promise for Rare, Deadly Cancer Caused by Asbestos Perelman School of Medicine at the University of Pennsylvania 2011-06-02 Photodynamic therapy added to lung sparing surgery provides superior results for overall survival in mesothelioma patients. NYU Cancer Institute Experts Present at the American Association for Cancer Research 102nd Annual Meeting 2011 New York University Langone Medical Center 2011-04-06 Experts from The Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Florida. NYU Cancer Institute researchers discussed various breakthroughs such as a novel test for early-stage asbestos-related pulmonary cancer, a promising treatment strategy for glioblastomas, genome-wide mapping of nickel-related cancer and greater understanding of melanoma and bladder cancer. New Test Detects Early-Stage, Asbestos-Related Pulmonary Cancer New York University Langone Medical Center 2011-04-04 Researchers at NYU Langone Medical Center have investigated a novel protein test to detect earlystage, asbestos-related pulmonary cancer. The test can accurately identify proteins secreted from Hitt Medical Writing, LLC © 2011


Page 8

Mesothelioma HittPackTM cancerous tumors caused by asbestos exposure. The study was presented at the American Association for Cancer Research 102nd Annual Meeting 2011 on April 4th. Mesothelima Cases Likely Are Significantly Underreported Worldwide Environmental Health Perspectives (NIEHS) 2011-01-06 For every four to five reported cases of mesothelioma worldwide, at least one case goes unreported, according to estimates published online January 6 ahead of print in the peer-reviewed journal Environmental Health Perspectives (EHP). This study is the first to provide a global estimate of unreported mesothelioma cases based on the collective experience of countries with available data on asbestos use and the disease.

Google.com Search term = “mesothelioma press releases”. First 10 results returned 1.

Researchers discover genetic link to mesothelioma - National ...

www.cancer.gov/newscenter/pressreleases/2011/MesotheliomaBAP1 Aug 26, 2011 - Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer – mesothelioma, and ... 2.

Mesothelioma News – 5 Things to Know About Mesothelioma ...

www.zimbio.com/.../Mesothelioma+News+5+Things+Know+Mesothe... Sep 28, 2011 - Mesothelioma Awareness Day Spurs the Hopes of Weitz & Luxenberg Co-Founder for …MarketWatch (press release) Today is Mesothelioma Awareness ... 3.

Press Release - Mesothelioma: Medical Risks and Liability Issues ...

www.24-7pressrelease.com/press-release/mesothelioma-medical-risks... Jul 3, 2011 - Press Release Distribution ... Mesothelioma is an aggressive cancer linked to asbestos exposure. Find out who may be liable for a mesothelioma diagnosis. ... 4.

Mesothelioma Cases Growing at an Alarming Rate – Expected to ...

www.prweb.com/releases/2011/7/prweb8603237.htm



Page 9

Mesothelioma HittPackTM Jul 18, 2011 - Asbestos exposure can cause Mesothelioma, a debilitating and often life-claiming disease. ... PRWeb News Center ... Past News Releases Group Rss ... 5.

Genetic Mutation Linked to Mesothelioma

www.survivingmesothelioma.com/news/view.asp?ID=001142 Aug 31, 2011 - “NIH-funded researchers discover genetic link to mesothelioma”, NCI Press Release, August 26, 2011. “BAP1 Gene Mutation Raises Mesothelioma and ... 6.

Mesothelioma Victims Center Urges US Navy ... - Yahoo! News

news.yahoo.com/mesothelioma-victims-center-urges-us-navy-veteran... Sep 6, 2011 - Why does the Mesothelioma Victims Center mention US Navy Veterans so often in its news articles, or press releases? The Mesothelioma Victims Center says, ... 7.

Striking Mesothelioma and asbestos related death statistics from UK ...

localizedusa.com/.../striking-mesothelioma-and-asbestos-related-deat... Aug 19, 2011 - plaguesBBC NewsUK Government Releases 'Shocking' Mesothelioma Stats Surviving Mesothelioma Localized USA -San Francisco Chronicle (press release) ... 8.

phase 2 trials - MesoRFA Information and Press Releases

www.mesorfa.info/mesothelioma-treatment-veglin-clinical-trial-phase... Aug 20, 2011 - Dr. Gill announces that phase 2 clinical trials will resume in the next month for Veglin, a successful treatment for mesothelioma lung cancer. 9.

A Mesothelioma Gene? | Cancer Minute | GenomeWeb

www.genomeweb.com › Cancer Minute Aug 30, 2011 - Researchers led by Fox Chase Cancer Center's Joseph Testa have discovered a possible genetic link to mesothelioma, says an NIH press release. In a new ... 10.

Merck Mesothelioma Drug Zolinza Fails in Phase III of Clinical Trial ...

www.asbestos.com › Mesothelioma News Sep 28, 2011 - (2011, September 23). Study of Zolinza for Investagational Use for Advanced Malignant Pelural Mesothelioma Did Not Meet Primary Endpoint [Press Release] ...



Page 10


IV. US Food and Drug Administration Info on Mesothelioma Drugs@FDA Database Original New Drug Approvals (NDAs and BLAs) by Month; last 3 months listed http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.ReportsMenu September 2011 Drug Name and FDA Appl. #

Active Ingredients

NDA Chem. Review Company Approval Type * ClassifiDate cation **

PUR-WASH (NDA # 022305)

PURIFIED WATER

5

S

NIAGARA 09/01/2011 PHARMA INC

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE (NDA # 202171)

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE

4

S

MATRIX 09/08/2011 LABS LTD

LAMIVUDINE; ZIDOVUDINE (NDA # 201151)

LAMIVUDINE; ZIDOVUDINE

CIPLA LIMITED

09/22/2011

MEMANTINE MEMANTINE HYDROCHLORIDE HYDROCHLORIDE (NDA # 200155)

TORRENT 09/27/2011 PHARMS

CLOBETASOL PROPIONATE (NDA # 201402)

PERRIGO 09/27/2011 ISRAEL

CLOBETASOL PROPIONATE

August 2011 Hitt Medical Writing, LLC © 2011


Page 11


GEMCITABINE (NDA # 200795)

GEMCITABINE HYDROCHLORIDE

3

S

HOSPIRA INC

08/04/2011

ROSUVASTATIN ZINC (NDA # 202172)

ROSUVASTATIN ZINC

2

S

WATSON LABS INC

08/04/2011

COMPLERA (NDA # 202123)

EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE

4

P

GILEAD SCIENCES INC

08/10/2011

ZELBORAF (NDA # 202429)

VEMURAFENIB

1

P

HOFFMAN 08/17/2011 N LA ROCHE

ADCETRIS (BLA # 125388)

BRENTUXIMAB VEDOTIN

SEATTLE 08/19/2011 GENETICS

ADCETRIS (BLA # 125399)

BRENTUXIMAB VEDOTIN

SEATTLE 08/19/2011 GENETICS

FIRAZYR (NDA # 022150)

ICATIBANT ACETATE

1

P

SHIRE ORPHAN THERAP

08/25/2011

NUCYNTA ER (NDA # 200533)

TAPENTADOL HYDROCHLORIDE

3

S

ORTHO MCNEIL JANSSEN

08/25/2011

XALKORI (NDA # 202570)

CRIZOTINIB

1

P

PFIZER

08/26/2011

July 2011

Drug Name and FDA Appl. #

Active Ingredients


NDA Chem. Review Company Type * Classification **


Approval Date

Page 12


ARCAPTA NEOHALER INDACATEROL (NDA # 022383) MALEATE

1

S

NOVARTIS

07/01/2011

XARELTO (NDA # 022406)

RIVAROXABAN

1

S

JOHNSON AND JOHNSON

07/01/2011

BRILINTA (NDA # 022433)

TICAGRELOR

1

S

ASTRAZENECA LP 07/20/2011

HEPARIN SODIUM (NDA # 201370)

HEPARIN SODIUM

5

S

PFIZER

07/21/2011

HEPARIN SODIUM PRESERVATIVE FREE (NDA # 201370)

HEPARIN SODIUM

5

S

PFIZER

07/21/2011

EPINEPHRINE (NDA # 201739)

EPINEPHRINE

INTELLIJECT INC. 07/29/2011

2011 Advisory Committee Meetings http://www.fda.gov/AdvisoryCommittees/Calendar/ucm153468.htm

V.

Guidelines in Mesothelioma



Page 13

Mesothelioma HittPackTM National Guidelines Clearinghouse--Guidelines.gov www.guidelines.gov; Search criteria = “mesothelioma” all years, sorted by date, all listed 1.

Lung cancer and cancer of the pleura. In: Pulmonary (acute & chronic). 2009 Jan. NGC:007588 Work Loss Data Institute - For Profit Organization. View all guidelines by the developer(s)

Compare Selected 32616 0

2.

Metastatic spinal cord compression. Diagnosis and management of adults Compare at risk of and with metastatic spinal cord compression. 2008 Nov. Selected NGC:007194 24592 National Collaborating Centre for Cancer - National Government Agency 0 [Non-U.S.]. View all guidelines by the developer(s)

3.

Pemetrexed for the treatment of malignant pleural mesothelioma. 2008 Jan. NGC:006979 National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)

Compare Selected 24115

0

4.

Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical Compare practice guidelines. (2nd Edition) 2007 Sep. NGC:005943 Selected American College of Chest Physicians - Medical Specialty Society. View all 23807 guidelines by the developer(s) 0

5.

The role of radiation therapy in malignant pleural mesothelioma: a clinical practice guideline. 2006 Feb 6. NGC:005594 Program in Evidence-based Care - State/Local Government Agency [NonU.S.]. View all guidelines by the developer(s)

Compare Selected 15656 0

National Comprehensive Cancer Network Hitt Medical Writing, LLC © 2011


Page 14

Mesothelioma HittPackTM Free password required www.nccn.org NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) in Malignant Pleural Mesothelioma http://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf European Society for Medical Oncology (ESMO) www.esmo.org Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup http://annonc.oxfordjournals.org/content/21/suppl_5/v126.full

VI. Conferences and Medical Associations for Mesothelioma Conferences    

European Lung Cancer Conference (ELCC) http://www.esmo.org/events/lung-2012-elcc.html American Society of Clinical Oncology (ASCO) annual meeting http://chicago2012.asco.org/ European Respiratory Society (ERS) Annual Congress http://www.erscongress2012.org/ Multidisciplinary Symposium in Thoracic Oncology http://www.thoracicsymposium.org/

Medical Associations 

American Association for Cancer Research (AACR)



American Cancer Society (ACS)



American Institute for Cancer Research (AICR)



American Lung Association (ALA)



International Mesothelioma Interest Group (iMig)



American Society of Clinical Oncology (ASCO)



Society of Thoracic Surgeons (STS)



European Respiratory Society



European Society for Medical Oncology (ESMO)

VII. Key Opinion Leaders in Mesothelioma A listing of key opinion leaders (KOLs) in mesothelioma who have participated in recent CME activities available online. Where possible, the sponsor information has been listed. Hitt Medical Writing, LLC © 2011


Page 15

Mesothelioma HittPackTM 

Dean A Fennell, BSc, MBBS, MRCP, PhD, Cancer Research UK Clinician Scientist; Consultant; Senior Lecturer, Medical Oncology, Queen's University Belfast, Northern Ireland Cancer Centre, Belfast, Northern Ireland, United Kingdom. Disclosure: Dean A. Fennell, BSc, MBBS, MRCP, PhD, has disclosed no relevant financial relationships.



Kenneth J O'Byrne, MD, Clinical Director, Hematology, Oncology, and Palliative Care Services, St. James's Hospital, Dublin, Republic of Ireland. No relevant financial relationships.



Jan van Meerbeeck, MD, PhD, Head, Unit of Thoracic Oncology, University Hospital Ghent; Professor, Thoracic Oncology, Ghent University, Ghent, Belgium. Disclosure: Jan van Meerbeeck, MD, PhD, has disclosed no relevant financial relationships.



David S Ettinger, MD, Alex Grass Professor of Oncology and Professor of Medicine, Otolaryngology-Head and Neck Surgery, Obstetrics and Gynecology, and Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Disclosure: Consultant/Speakers Bureau: AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, MGI, Pfizer; Advisory Board: AstraZeneca, Aventis, Bristol-Myers Squibb, Cell Therapeutics, Eli Lilly, GlaxoSmithKline, Merck, MGI, Pfizer; Grant Support: Aventis, Eli Lilly.



Mark A Socinski, MD, Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, NC. Disclosure: Grant/Research Support: Eli Lilly and Company; Speaker's Bureau: Eli Lilly and Company; Consultant: Eli Lilly and Company.



Nicholas J Vogelzang, MD, Director, Nevada Cancer Institute, Las Vegas, Nevada; Professor, University of Nevada School of Medicine, Las Vegas, Nevada. Disclosure: Grant/Research Support: Abbott, The American Cancer Society, Alfacell, AstraZeneca, Eli Lilly and Company, Medarex, the National Cancer Institute, Yamanouchi; Speaker's Bureau: Aventis, Celgene, Eli Lilly and Company, Novartis, Praecis; Advisory Board: Abbott Advance Life Sciences, GPC, Merck, OSI, Praecis; Consultant: Eli Lilly and Company.



Winston W Tan, MD, Assistant Professor of Medicine, Mayo Medical School; Consulting Staff, Mayo Group Practices. Disclosure: Medivation Grant/research funds; Oncogenix Grant/research funds; Genentech Grant/research funds



Benjamin Movsas, MD, Vice-Chairman, Department of Radiation Oncology, Fox Chase Cancer Center. Disclosure: Nothing to disclose.



Jules E Harris, MD, Clinical Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine; Consulting Staff, Arizona Cancer Center. Disclosure: GlobeImmune Salary Consulting.

VIII. Clinical Trials in Progress in Mesothelioma Clinical trials.gov Search criteria- mesothelioma | Open Studies | Exclude Unknown | Phase II, III, IV



Page 16

Mesothelioma HittPackTM 27 studies, first 20 listed 1

2

3

4

5

6

Recruiting

Recruiting

Recruiting

Recruiting

Not yet recruiting

Not yet recruiting

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Conditions:

Pleural Mesothelioma; Peritoneal Mesothelioma

Intervention:

Drug: IMC-A12

Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma Conditions:

Mesothelioma; Pleural Mesothelioma

Interventions:

Drug: Pemetrexed; Drug: Cisplatin

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Condition:

Malignant Mesothelioma

Interventions:

Drug: cediranib maleate; Drug: cisplatin; Drug: pemetrexed disod placebo

Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II) Conditions:

Malignant Pleural Mesothelioma; MPM; Solid Tumors

Interventions:

Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and c

A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma Condition:

Malignant Pleural Mesothelioma

Interventions:

Drug: Cisplatin; Drug: Pemetrexed; Drug: Vorinostat; Drug: Plac

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma



Page 17


7

8

9

Recruiting

Recruiting

Recruiting

10 Recruiting

11 Recruiting

Condition:


Interventions:

Biological: rilotumumab; Drug: cisplatin; Drug: pemetrexed disod boratory biomarker analysis

Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Condition:


Interventions:

Drug: cisplatin; Drug: pemetrexed disodium; Other: diagnostic la analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant t quality-oflife assessment; Procedure: therapeutic conventional surgery; Ra erapy

Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy Condition:


Interventions:

Drug: pemetrexed disodium; Other: clinical observation

Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Condition:


Intervention:

Drug: everolimus

Axitinib in Malignant Mesothelioma Condition:


Interventions:

Biological: axitinib; Drug: chemotherapy

A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Condition:


Intervention:

Drug: ADI-PEG 20



Page 18


12 Recruiting

13 Recruiting

14 Recruiting

15 Recruiting

16 Recruiting

17 Recruiting

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma Condition:

Advanced Malignant Pleural Mesothelioma

Interventions:

Drug: NGRhTNF; Drug: Placebo; Other: Best Supportive Care

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Condition:


Intervention:

Drug: GC1008

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Condition:

Mesothelioma

Interventions:

Drug: Standard Chemotherapy (Pemetrexed and Cisplatin); Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Conditions:

Lung Cancer; Esophageal Cancer; Malignant Pleural Mesotheliom Thymic Carcinoma

Interventions:

Biological: Allogeneic Tumor Cell Vaccine (K562); Drug: Celecoxib; osphamide

Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Condition:

Mesothelioma

Intervention:

Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)

Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity



Page 19


Modulated Radiation Therapy

18 Recruiting

19 Recruiting

20 Recruiting

Condition:

Mesothelioma

Intervention:

Other: Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy

Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Condition:


Interventions:

Biological: WT-1-vaccine Montanide + GMCSF; Biological: Montanide adjuvant + GM-CSF

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) Condition:

Mesothelioma

Intervention:

Drug: Zometa (zoledronic acid)

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Condition:

Pleural Mesothelioma

Intervention:

Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)

IX. PubMed Search in Mesothelioma http://www.ncbi.nlm.nih.gov/pubmed/ Search = mesothelioma, published in the last year, English only Randomized Controlled Trials Results: 0 Hitt Medical Writing, LLC © 2011


Page 20


Reviews Results: 13 in last 180 days 1. Magnetic resonance imaging of cardiac tumors: part 2, malignant tumors and tumor-like conditions. Randhawa K, Ganeshan A, Hoey ET. Curr Probl Diagn Radiol. 2011 Jul-Aug;40(4):169-79. Review. PMID: 21616279 [PubMed - indexed for MEDLINE] Related citations 2. Review on clinical trials of targeted treatments in malignant mesothelioma. Jakobsen JN, Sørensen JB. Cancer Chemother Pharmacol. 2011 Jul;68(1):1-15. Epub 2011 May 7. Review. PMID: 21553148 [PubMed - indexed for MEDLINE] Related citations 3. The diminishing role of surgery in pleural disease. Davies HE, Rosenstengel A, Lee YC. Curr Opin Pulm Med. 2011 Jul;17(4):247-54. Review. PMID:



Page 21

Mesothelioma HittPackTM 21537191 [PubMed - indexed for MEDLINE] Related citations 4. Gene therapy for mesothelioma. Vachani A, Moon E, Albelda SM. Curr Treat Options Oncol. 2011 Jun;12(2):173-80. Review. PMID: 21519819 [PubMed - indexed for MEDLINE] Related citations 5. Outcome of patients with nonspecific pleuritis at thoracoscopy. Wrightson JM, Davies HE. Curr Opin Pulm Med. 2011 Jul;17(4):242-6. Review. PMID: 21519267 [PubMed - indexed for MEDLINE] Related citations 6. Update on malignant pleural mesothelioma. Campbell NP, Kindler HL. Semin Respir Crit Care Med. 2011 Feb;32(1):102-10. Epub 2011 Apr 15. Review. PMID: Hitt Medical Writing, LLC © 2011


Page 22

Mesothelioma HittPackTM 21500129 [PubMed - indexed for MEDLINE] Related citations 7. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, Moons KG. Br J Cancer. 2011 Apr 12;104(8):1325-33. Epub 2011 Mar 29. Review. PMID: 21448170 [PubMed - indexed for MEDLINE] Related citations 8. Novel targeted therapies and vaccination strategies for mesothelioma. Bagia M, Nowak AK. Curr Treat Options Oncol. 2011 Jun;12(2):149-62. Review. PMID: 21424750 [PubMed - indexed for MEDLINE] Related citations 9. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma? Zahid I, Sharif S, Routledge T, Scarci M. Interact Cardiovasc Thorac Surg. 2011 May;12(5):812-7. Epub 2011 Feb 22. Review.



Page 23

Mesothelioma HittPackTM PMID: 21345818 [PubMed - indexed for MEDLINE] Free Article Related citations 10. Asbestos-related disease. Jamrozik E, de Klerk N, Musk AW. Intern Med J. 2011 May;41(5):372-80. doi: 10.1111/j.1445-5994.2011.02451.x. Review. PMID: 21309996 [PubMed - indexed for MEDLINE] Related citations 11. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. Baratti D, Kusamura S, Deraco M. J Surg Oncol. 2011 Jun;103(8):822-31. doi: 10.1002/jso.21787. Epub 2011 Jan 31. Review. PMID: 21283990 [PubMed - indexed for MEDLINE] Related citations 12. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?



Page 24

Mesothelioma HittPackTM Sharif S, Zahid I, Routledge T, Scarci M. Interact Cardiovasc Thorac Surg. 2011 May;12(5):806-11. Epub 2011 Jan 25. Review. PMID: 21266493 [PubMed - indexed for MEDLINE] Free Article Related citations 13. Malignant pleural mesothelioma: the standard of care and challenges for future management. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Crit Rev Oncol Hematol. 2011 May;78(2):92-111. Epub 2010 May 13. Review. PMID: 20466560 [PubMed - indexed for MEDLINE] Related citations

Editorials Results: 1 in last 180 days 1. Facts, rumours and speculations about the mesothelioma epidemic. van Meerbeeck JP, Damhuis R. Respirology. 2011 Oct;16(7):1018-9. doi: 10.1111/j.1440-1843.2011.02020.x. No abstract available. PMID: 21749551



Page 25

Mesothelioma HittPackTM [PubMed - in process] Related citations



Page 26

Mesothelioma - Hitt Medical Writing, LLC

Mesothelioma - Hitt Medical Writing, LLC

Suggest Documents

Equipment and Software for Medical Writers - Hitt Medical Writing, LLC

San Lucas Medical, LLC

04 clemons - Lorin Hitt

San Lucas Medical, LLC

San Lucas Medical, LLC

San Lucas Medical, LLC

San Lucas Medical, LLC

Hitt 2-17 - Wilderness.net

Righting Medical Writing

Effective Medical Writing

Writing and Personal Growth - LeFlore Communications, LLC

Effective Medical Writing - MongolMed

Righting Medical Writing

Medical Franchising - Pannone Lopes Devereaux & O'Gara LLC

Urgent Medical Staffing Solutions, LLC

Geriatric emergency medicine - Stall Senior Medical LLC

HITT or Miss - Semantic Scholar

San Lucas Medical, LLC - RJ Lee Group

Patient Monitoring Equipment & Accessories - Pacific Medical LLC

greathouse medical transportation, llc cuyahoga county medicaid ...

Writing a medical case report

medical writing - Firma Clinical Research

Plagiarism and medical writing

Academic Writing Development in the LLC Program - Centre for ...